We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

2gbc

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="2gbc" size="450" color="white" frame="true" align="right" spinBox="true" caption="2gbc, resolution 2.800&Aring;" /> '''Native DPP-IV (CD26...)
Line 1: Line 1:
-
[[Image:2gbc.gif|left|200px]]<br /><applet load="2gbc" size="450" color="white" frame="true" align="right" spinBox="true"
+
[[Image:2gbc.gif|left|200px]]<br /><applet load="2gbc" size="350" color="white" frame="true" align="right" spinBox="true"
caption="2gbc, resolution 2.800&Aring;" />
caption="2gbc, resolution 2.800&Aring;" />
'''Native DPP-IV (CD26) from Rat'''<br />
'''Native DPP-IV (CD26) from Rat'''<br />
==Overview==
==Overview==
-
Dipeptidyl peptidase IV (DPP-IV) belongs to a family of serine peptidases, and due to its indirect regulatory role in plasma glucose modulation, DPP-IV has become an attractive pharmaceutical target for diabetes, therapy. DPP-IV inactivates the glucagon-like peptide (GLP-1) and several, other naturally produced bioactive peptides that contain preferentially a, proline or alanine residue in the second amino acid sequence position by, cleaving the N-terminal dipeptide. To elucidate the details of the active, site for structure-based drug design, we crystallized a natural source, preparation of DPP-IV isolated from rat kidney and determined its, three-dimensional structure using X-ray diffraction techniques. With a, high degree of similarity to structures of human DPP-IV, the active site, architecture provides important details for the design of inhibitory, compounds, and structures of inhibitor-protein complexes offer detailed, insight into three-dimensional structure-activity relationships that, include a conformational change of Tyr548. Such accommodation is, exemplified by the response to chemical substitution on 2-cyanopyrrolidine, inhibitors at the 5 position, which conveys inhibitory selectivity for, DPP-IV over closely related homologues. A similar conformational change is, also observed in the complex with an unrelated synthetic inhibitor, containing a xanthine core that is also selective for DPP-IV. These, results suggest the conformational flexibility of Tyr548 is unique among, protein family members and may be utilized in drug design to achieve, peptidase selectivity.
+
Dipeptidyl peptidase IV (DPP-IV) belongs to a family of serine peptidases, and due to its indirect regulatory role in plasma glucose modulation, DPP-IV has become an attractive pharmaceutical target for diabetes therapy. DPP-IV inactivates the glucagon-like peptide (GLP-1) and several other naturally produced bioactive peptides that contain preferentially a proline or alanine residue in the second amino acid sequence position by cleaving the N-terminal dipeptide. To elucidate the details of the active site for structure-based drug design, we crystallized a natural source preparation of DPP-IV isolated from rat kidney and determined its three-dimensional structure using X-ray diffraction techniques. With a high degree of similarity to structures of human DPP-IV, the active site architecture provides important details for the design of inhibitory compounds, and structures of inhibitor-protein complexes offer detailed insight into three-dimensional structure-activity relationships that include a conformational change of Tyr548. Such accommodation is exemplified by the response to chemical substitution on 2-cyanopyrrolidine inhibitors at the 5 position, which conveys inhibitory selectivity for DPP-IV over closely related homologues. A similar conformational change is also observed in the complex with an unrelated synthetic inhibitor containing a xanthine core that is also selective for DPP-IV. These results suggest the conformational flexibility of Tyr548 is unique among protein family members and may be utilized in drug design to achieve peptidase selectivity.
==About this Structure==
==About this Structure==
-
2GBC is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus] with NAG and NDG as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Peptidyl-dipeptidase_Dcp Peptidyl-dipeptidase Dcp], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.15.5 3.4.15.5] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2GBC OCA].
+
2GBC is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus] with <scene name='pdbligand=NAG:'>NAG</scene> and <scene name='pdbligand=NDG:'>NDG</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Peptidyl-dipeptidase_Dcp Peptidyl-dipeptidase Dcp], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.15.5 3.4.15.5] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2GBC OCA].
==Reference==
==Reference==
Line 14: Line 14:
[[Category: Rattus norvegicus]]
[[Category: Rattus norvegicus]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Fry, E.H.]]
+
[[Category: Fry, E H.]]
-
[[Category: Jakob, C.G.]]
+
[[Category: Jakob, C G.]]
-
[[Category: Longenecker, K.L.]]
+
[[Category: Longenecker, K L.]]
[[Category: Wilk, S.]]
[[Category: Wilk, S.]]
[[Category: NAG]]
[[Category: NAG]]
Line 22: Line 22:
[[Category: beta propeller]]
[[Category: beta propeller]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 11:05:40 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:30:00 2008''

Revision as of 15:30, 21 February 2008


2gbc, resolution 2.800Å

Drag the structure with the mouse to rotate

Native DPP-IV (CD26) from Rat

Overview

Dipeptidyl peptidase IV (DPP-IV) belongs to a family of serine peptidases, and due to its indirect regulatory role in plasma glucose modulation, DPP-IV has become an attractive pharmaceutical target for diabetes therapy. DPP-IV inactivates the glucagon-like peptide (GLP-1) and several other naturally produced bioactive peptides that contain preferentially a proline or alanine residue in the second amino acid sequence position by cleaving the N-terminal dipeptide. To elucidate the details of the active site for structure-based drug design, we crystallized a natural source preparation of DPP-IV isolated from rat kidney and determined its three-dimensional structure using X-ray diffraction techniques. With a high degree of similarity to structures of human DPP-IV, the active site architecture provides important details for the design of inhibitory compounds, and structures of inhibitor-protein complexes offer detailed insight into three-dimensional structure-activity relationships that include a conformational change of Tyr548. Such accommodation is exemplified by the response to chemical substitution on 2-cyanopyrrolidine inhibitors at the 5 position, which conveys inhibitory selectivity for DPP-IV over closely related homologues. A similar conformational change is also observed in the complex with an unrelated synthetic inhibitor containing a xanthine core that is also selective for DPP-IV. These results suggest the conformational flexibility of Tyr548 is unique among protein family members and may be utilized in drug design to achieve peptidase selectivity.

About this Structure

2GBC is a Single protein structure of sequence from Rattus norvegicus with and as ligands. Active as Peptidyl-dipeptidase Dcp, with EC number 3.4.15.5 Full crystallographic information is available from OCA.

Reference

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors., Longenecker KL, Stewart KD, Madar DJ, Jakob CG, Fry EH, Wilk S, Lin CW, Ballaron SJ, Stashko MA, Lubben TH, Yong H, Pireh D, Pei Z, Basha F, Wiedeman PE, von Geldern TW, Trevillyan JM, Stoll VS, Biochemistry. 2006 Jun 20;45(24):7474-82. PMID:16768443

Page seeded by OCA on Thu Feb 21 17:30:00 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools